FDA gives fast-track designation to Arca biopharma’s COVID treatment
WESTMINSTER — A potential therapy for severe COVID-19 patients being developed by Arca Biopharma Inc. (Nasdaq: ARCA) received a fast-track […]
Source: BizWest
Related Articles
BizWest celebrates 40 years covering business and recognizes 40 iconic leaders who inspired the region’s development.
View related stories: Click here to view the 40th Anniversary supplement. ‘Turnpike’ helps define how economy has changed Wood: Preserving…
ARCA Biopharma submits anti-blood clotting drug to FDA as potential COVID treatment
WESTMINSTER — Gene therapy maker ARCA biopharma Inc. (Nasdaq: ABIO) has filed an initial application to study whether its anti-blood…
Spur-of-the-moment decision results in Louisville startup
LOUISVILLE — He had a choice while driving over a bridge in Yemen where he was studying Arabic. Either hit…
CEO Roundtable: Health care execs look to challenges beyond pandemic
BOULDER — With the COVID-19 pandemic in the rear-view mirror, health care executives are dealing with challenges such as continuing…
Arca Biopharma: Losses lower, no M&A decision in first quarter
BOULDER — At the end of the first quarter of 2023, a period in which Arca Biopharma Inc. (Nasdaq: ABIO)…